Connect with us

Technology

NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Published

on

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancerCorrelative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPICombination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results

ROCKVILLE, Md., June 3, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference.

NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated.

Key findings from NIT-110 include:

Pancreatic cancer – Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond.MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2].

These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments.

A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes.

Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies.

NeoImmuneTech’s CEO, Luke Oh, PhD, said: “We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market.”

Posters references:

Abstract #

Track

Poster board #

Title

2621 (Link)

Developmental Therapeutics -Immunotherapy

100

A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors

2563

(Link)

Developmental Therapeutics -Immunotherapy

42

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors

2043

(Link)

Central Nervous System Tumors

342

Expand and pull: a new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy

 

About Study NIT-110
NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts.

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1
[2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

VPN Proxy Master Leads the 2024 VPN Market with New Features and Holiday Deals

Published

on

By

SINGAPORE, Dec. 22, 2024 /PRNewswire/ — As the demand for online privacy reaches unprecedented levels, the global VPN market has seen a remarkable surge of over 30% in 2024. Addressing this growing need for secure and unrestricted internet access, VPN Proxy Master, a trusted name in network security, has introduced significant updates and exclusive offers to empower users worldwide.

A Growing Need for Privacy: VPN Market Trends in 2024

With increasing concerns over cybersecurity, the VPN market has become essential for professionals and everyday users alike. The growth in 2024 has been driven by heightened awareness of data privacy, as cyber threats and public Wi-Fi risks make secure browsing a top priority.

VPN Proxy Master continues to lead the charge in the cyber security space, offering cutting-edge security features that protect users from various online vulnerabilities. From securing sensitive work documents to maintaining anonymity while streaming, VPN Proxy Master is designed to meet the diverse needs of its growing user base.

Enhanced Features for Windows Users

One of VPN Proxy Master’s most exciting updates for 2024 is the introduction of seven free server options for Windows users, expanding access far beyond the single US-based server previously available. This feature ensures a smoother and more flexible browsing experience, allowing users to choose the best connection for their location and needs.

“Our goal has always been to provide users with unparalleled convenience and security,” says a VPN Proxy Master spokesperson. “This update is part of our commitment to creating a user-friendly platform that exceeds expectations.”

Why Users Choose VPN Proxy Master

With over 6,000 fully encrypted servers worldwide, VPN Proxy Master has become a preferred choice for professionals and individuals seeking secure online solutions. The platform’s top features include:

100% No-Log Policy: User activity is never tracked or storedAES 256-Bit Encryption: The highest standard of online securityMulti-Device Coverage: Protect up to six devices simultaneouslyExceptional User Reviews: High ratings from satisfied customersLightning-Fast Connections: Optimised servers ensure speed without compromise

Users Are Empowering Online Freedom

Across the globe, VPN Proxy Master users are benefiting from its powerful features.

Jonathan, a frequent traveler from the US, shares: “I rely on VPN Proxy Master to access work files securely when I’m on public Wi-Fi. It’s fast, reliable, and keeps my data safe.”Sophie, a digital nomad from the UK, adds: “Online privacy is non-negotiable for me. VPN Proxy Master ensures I can browse and work securely, no matter where I am.”

These testimonials illustrate how VPN Proxy Master not only protects users but also enhances their productivity and peace of mind.

Celebrate the Holidays with a Special Christmas Offer

As a token of appreciation for its loyal users, VPN Proxy Master is introducing an exclusive Christmas promotion. From now until January 2, 2025, customers purchasing a VPN subscription will receive an additional three months of service free. This limited-time offer provides an excellent opportunity for users to safeguard their online activities during the festive season and into the new year.

The Most Secure Global VPN for Professionals

VPN Proxy Master’s dedication to innovation and user-focused solutions has cemented its position as a leader in the industry. With a no-log policy, AES 256-bit encryption, and multi-device support, the platform is designed for users who value privacy, efficiency, and reliability.

Join the VPN Proxy Master Community

The company’s mission is to make the Internet a safer and more accessible space for all. Whether you’re a professional protecting sensitive work data, a student seeking unrestricted access to resources, or a family looking to enhance online safety, VPN Proxy Master has the right solution for you.

To learn more about VPN Proxy Master, explore its features, or take advantage of the Christmas promotion, visit the official website at vpnproxymaster.com or follow our X account: https://x.com/VPNProxyMaster_ for the latest updates and offers.

About VPN Proxy Master
VPN Proxy Master is a flagship product of Lemon Clove Pte. Limited, committed to delivering advanced VPN technology to users worldwide. With an emphasis on privacy, security, and reliability, the platform empowers users to take control of their digital experiences in an increasingly connected world.

For inquiries, please contact:
Email: support@vpnproxymaster.com 

This holiday season, give yourself the gift of online security with VPN Proxy Master—where privacy and performance meet.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vpn-proxy-master-leads-the-2024-vpn-market-with-new-features-and-holiday-deals-302338031.html

SOURCE VPN Proxy Master

Continue Reading

Technology

Goldpac Wins the 2024 KPMG China Corporate Governance Pioneers Award

Published

on

By

HONG KONG, Dec. 23, 2024 /PRNewswire/ — Recently, KPMG China announced the winners of the Second KPMG ESG 50 Awards • 2024. Goldpac was awarded with the Corporate Governance Pioneers with its outstanding performance in terms of governance structures, decision-making mechanisms, internal control, information disclosure, protection of shareholders’ equity, etc. 

As the leading fintech enterprise around the globe, Goldpac has always maintained good profitability since its listing, and has achieved a total revenue of RMB 16.1 billion and a total profit of RMB 1.9 billion, remaining leading profitability in the industry. While committing itself to steady growth, Goldpac also maintains an active and stable dividend policy to actively return to its shareholders.

At the same time, Goldpac attaches great importance on technology development and sustainable growth. Riding the wave of global digitalisation, Goldpac is accelerating the promotion of its digital and platform-based strategy, using the UMV platform that integrates cutting-edge technologies such as AI and big data to build an innovative ecosystem of secure payment chain with upstream and downstream industry participants. Moreover, Goldpac also continues to promote the expansion of secure payment chips into multiple fields, broadening its service territory.

Goldpac always combines its business operations with the co-development of the environment and the society, and has established an effective ESG governance system covering ESG objectives such as energy saving and emission reduction, promotion of green and low-carbon products, green procurement, digital construction, competitiveness and profitability.

Regarding the protection of shareholders’ equity, Goldpac adopts sufficient and effective information disclosure and market communication strategies to maintain good transparency, which is acknowledged by the capital market. Therefore,  Goldpac was awarded with many honors like the “Best Shareholder Return Listed Company”, the “Most Social Responsible Listed Company” , building a sustainable internal and external ecology. 

In recent years, ESG practices have become one of the key elements for corporate value realisation and resilient growth. Looking ahead, Goldpac will adhere to the global ESG development trend, give full play to its advantages in financial technology, and continuously improve its digital competitiveness to promote sustainable economic and social development.

View original content:https://www.prnewswire.com/apac/news-releases/goldpac-wins-the-2024-kpmg-china-corporate-governance-pioneers-award-302337109.html

SOURCE Goldpac Group

Continue Reading

Technology

JA Solar and Huawei Collaborate with UNESCO and Thailand’s Ministry of Education to Advance Green Education

Published

on

By

BEIJING, Dec. 23, 2024 /PRNewswire/ — JA Solar, a global leader in the PV industry, recently joined forces with Huawei, UNESCO, and Thailand’s Ministry of Education to launch a green education initiative at the Banna District Learning Encouragement Center in Nakhon Nayok Province, Thailand. The project aims to provide clean energy solutions and digital education opportunities to 11 schools and community centers, fostering a new generation equipped with green skills and digital literacy.

As a key component of this initiative, JA Solar donated its high-efficiency n-type PV modules, DeepBlue 4.0 Pro, to schools, deeply engaging in the construction of a green school education system by installing solar PV and energy storage equipment in multiple middle schools, and providing training on the application and management of green energy for teachers and students to help them understand the practical value of clean energy. DeepBlue 4.0 Pro, renowned for its high conversion efficiency and high reliability, enabling schools to achieve a sustainable clean energy supply.

Moreover, JA Solar is committed to enhancing vocational education by helping schools establish dedicated training bases for solar PV system installation. Through comprehensive practical courses, students gain vital skills in installation, maintenance, and operation of PV systems, preparing them for future careers in the burgeoning renewable energy sector.

One of the project’s first implementation sites, Kanchanapisek Vocational Training College, is integrating the donated solar PV system into its teaching curriculum. Students benefit from simulated real-world installation and maintenance scenarios, gaining key employability skills. Meanwhile, at the Banna District Learning Encouragement Center, JA Solar and its partners installed solar energy storage systems for the community library and learning center. In addition, a “Digital Bus” was introduced to offer mobile digital education, providing free training on telecommunications, cybercrime awareness, and green energy to local residents and students. These efforts not only improve the community’s energy efficiency but also create valuable learning and development opportunities.

With plans to extend this program to additional schools and communities, JA Solar and its partners aim to maximize the dual benefits of green energy and digital education, contributing significantly to sustainable development in Thailand and globally.

“We are honored to contribute to Thailand’s green education project,” said Aiqing Yang, Executive President of JA Solar. “Upholding our mission of ‘Developing Solar Power to Benefit the Planet,’ this initiative not only accelerates Thailand’s energy transition but also empowers students with practical knowledge to build a sustainable future. Looking ahead, JA Solar will continue to deliver green energy solutions and educational resources to more regions, advancing together toward a low-carbon, sustainable future.”

Follow us on LinkedIn and Facebook  to know more about JA Solar.

 

SOURCE JA Solar Technology Co., Ltd.

Continue Reading

Trending